BioVie receives notice of allowance for Japan patent application

BioVie announced that it has received a Notice of Allowance from the Japan Patent Office for patent application no. 2021-569344 entitled “Formulations of Terlipressin.” This Notice of Allowance is expected to result in the issuance of a Japanese patent in 2 to 3 weeks once administrative processes are completed. The allowed claims cover a novel liquid formulation of terlipressin acetate that has stability at room temperature for two years and can be packaged in a pre-filled syringe. The patent supports BioVie’s liquid formulation of terlipressin for development of a more patient-centric ambulatory treatment regimen for patients with ascites and hepatic failure in the US.